Skip to main
ROIV

ROIV Stock Forecast & Price Target

ROIV Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 33%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Roivant Sciences is a commercial-stage biopharmaceutical company that is well-positioned for potential success with its diverse portfolio of drug candidates, including VTAMA and Batoclimab, in different stages of development. With a positive outlook on its clinical data and potential approvals, the company's valuation is expected to increase based on its revenue estimates. However, as with any biopharmaceutical company, there are regulatory and commercial risks that could impact the achievement of its price target, as well as technical risks related to the validation of its technology. Nonetheless, Roivant Sciences has demonstrated a strong track record of success in its clinical trials and has a promising pipeline with blockbuster potential. With its well-capitalized position and multiple upcoming catalysts, the company is on track to achieve profitability and potentially acquire or in-license additional assets. Overall, the company's focus on combination therapies and its positioning within the pulmonary hypertension landscape bode well for its future success in the biopharmaceutical industry.

Bears say

Roivant Sciences is facing challenges in diversifying its drug pipeline beyond its current commercial stage treatment, tapinarof. While the company has promising drug candidates in development for various indications such as plaque psoriasis, dermatomyositis, and non-infectious uveitis, their timeline for potential launches and potential efficacy compared to other candidates may not be competitive. Additionally, their pricing strategy for IMVT-1402 may face scrutiny from payers and may not be sustainable in the long term.

ROIV has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 33% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Roivant Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Roivant Sciences Ltd (ROIV) Forecast

Analysts have given ROIV a Buy based on their latest research and market trends.

According to 9 analysts, ROIV has a Buy consensus rating as of May 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.94, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.94, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Roivant Sciences Ltd (ROIV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.